Cargando…

Influence of gene expression on survival of clear cell renal cell carcinoma

Approximately 10%‐20% of patients with clinically localized clear cell renal cell carcinoma (ccRCC) at time of surgery will subsequently experience metastatic progression. Although considerable progression was seen in the systemic treatment of metastatic ccRCC in last 20 years, once ccRCC spreads be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berglund, Anders, Amankwah, Ernest K., Kim, Young‐Chul, Spiess, Philippe E, Sexton, Wade J., Manley, Brandon, Park, Hyun Y., Wang, Liang, Chahoud, Jad, Chakrabarti, Ratna, Yeo, Chang D., Luu, Hung N., Pietro, Giuliano D., Parker, Alexander, Park, Jong Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666730/ https://www.ncbi.nlm.nih.gov/pubmed/32986937 http://dx.doi.org/10.1002/cam4.3475

Ejemplares similares

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
por: Chatwal, Monica Sheila, et al.
Publicado: (2023)

Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
por: Chakiryan, Nicholas H, et al.
Publicado: (2023)

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2021)

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2022)

Telomere length in peripheral blood leukocytes and risk of renal cell carcinoma
por: Park, Jong Y., et al.
Publicado: (2019)

Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2021)

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
por: Zhang, Yumeng, et al.
Publicado: (2022)

Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
por: Adashek, Jacob J., et al.
Publicado: (2021)

Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2021)

An update on treatment of penile cancer
por: Chadha, Juskaran, et al.
Publicado: (2022)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas
por: Yao, Masahiro, et al.
Publicado: (2014)

The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
por: Ahmed, Mohamed E., et al.
Publicado: (2020)

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
por: Arakaki, Ryuichiro, et al.
Publicado: (2016)

Etiologic heterogeneity of clear‐cell and papillary renal cell carcinoma in the Netherlands Cohort Study
por: van de Pol, Jeroen A. A., et al.
Publicado: (2020)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2022)

An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma
por: Grass, G.Daniel, et al.
Publicado: (2023)

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
por: Gulati, Sakshi, et al.
Publicado: (2014)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma
por: Xu, Jianing, et al.
Publicado: (2019)

Preclinical evaluation of an unconventional ruthenium‐gold‐based chemotherapeutic: RANCE‐1, in clear cell renal cell carcinoma
por: Elie, Benelita T., et al.
Publicado: (2019)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm
por: Luo, Jun, et al.
Publicado: (2020)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma
por: Nakai, Takaaki, et al.
Publicado: (2017)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Prognostic predictors of lymph node metastasis in penile cancer: a systematic review
por: Zekan, David S., et al.
Publicado: (2021)

Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas
por: Arai, Eri, et al.
Publicado: (2015)

Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B
por: Liu, Junlong, et al.
Publicado: (2019)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
por: Franklin, Miriam, et al.
Publicado: (2018)

Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma
por: Lin, Shitong, et al.
Publicado: (2020)

Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome
por: Arai, Eri, et al.
Publicado: (2009)

Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation
por: Li, Yuqing, et al.
Publicado: (2020)

Ubiquitin‐specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF‐κB pathway inactivation
por: Gui, Dingwen, et al.
Publicado: (2021)

MicroRNA‐194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma
por: Nofech‐Mozes, Roy, et al.
Publicado: (2016)

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
por: Motzer, Robert, et al.
Publicado: (2023)

Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma
por: Narimatsu, Takahiro, et al.
Publicado: (2015)

Patterns of distant metastases in patients with clear cell renal cell carcinoma––A population‐based analysis
por: Xue, Jianxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k73tia10ksdhcie62aopddmmfk